RxDoctor Payments DataLook up a doctor →

Rodolfo Carrillo Jimenez, MD

Interventional Cardiology · Delray Beach, FLNPI 1871513754

Payments from drug & device makers

$384,123in general payments, 2019–2025

Across 1,091 payments — averaging $352.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$364K
  • Bayer$9K
  • Abbott$3K
  • Johnson & Johnson$1K
  • Boston Scientific$858
  • AstraZeneca$733
  • plus $5K from 38 others
$50in research payments, 2019–2025

Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$50

What the payments were for

  • Food & beverage$11,41198%
  • Education$2142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$384,123 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$621,996
Medicare patients
1,218
Services billed
6,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$425,820
XareltoRivaroxaban287$355,272
EntrestoSacubitril/Valsartan205$234,642
JardianceEmpagliflozin64$64,055
BrilintaTicagrelor70$48,897
MounjaroTirzepatide34$38,016
Repatha SureclickEvolocumab29$26,175
FarxigaDapagliflozin Propanediol22$17,995
Metoprolol Succinate472$4,120
Losartan Potassium404$2,870
Atorvastatin Calcium312$2,844
Carvedilol445$2,716
Rosuvastatin Calcium203$2,207
Ranolazine ErRanolazine32$2,201
Valsartan84$1,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$299$425,820379 claims
Johnson & JohnsonXarelto$1,210$355,272287 claims
NovartisEntresto$561$234,642205 claims
AstraZenecaBrilinta, Farxiga$733$66,89292 claims
Boehringer IngelheimJardiance$412$64,05564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →